Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Mannheim – page 22

357 clinical trials in Mannheim, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Mannheim at a glance
357
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

357 trials in Mannheim

Open in trial search

Cholangiocarcinoma+1

Not recruiting

Study on Gemcitabine and Cisplatin for Patients After Surgery for Bile Duct or Gallbladder Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:University Medical Center Hamburg-Eppendorf

Malignant peritoneal neoplasm+2

Not recruiting

Study of Rucaparib and Nivolumab for Maintenance Treatment in Patients with Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer After Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:pharmaand GmbH

Ovarian cancer

Not recruiting

Study of olaparib, durvalumab and UV1 combination as maintenance treatment for patients with recurrent ovarian cancer who do not have BRCA mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alrefimotide
  • Sponsor:Nordic Society Of Gynaecological Oncology Clinical Trial Unit

Type 2 diabetes mellitus

Not recruiting

Study on the Effects of AZD5004 and Semaglutide for Adults with Type 2 Diabetes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Autoimmune demyelinating disease

Not recruiting

Study on the Effects of Satralizumab for Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Squamous cell carcinoma of head and neck

Not recruiting

Study of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and Pembrolizumab for Patients with Advanced Head and Neck Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:ACP-017
  • Sponsor:Ascendis Pharma Oncology Division A/S

Ovarian epithelial cancer

Not recruiting

Study on the Effectiveness and Safety of Cyclophosphamide Monohydrate and Drug Combination for Patients with Persistent or Recurrent Rare Epithelial Ovarian Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:F. Hoffmann-La Roche AG

Type 2 diabetes mellitus

Not recruiting

Study Comparing Orforglipron and Dapagliflozin for Adults with Type 2 Diabetes and Poor Blood Sugar Control on Metformin

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Eli Lilly & Co.

Breast cancer+3

Not recruiting

Study of Capivasertib and Fulvestrant for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:AstraZeneca AB

Hypertension

Not recruiting

Study on Baxdrostat for Reducing Blood Pressure in Patients with Uncontrolled or Resistant Hypertension

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Autonomic nervous system imbalance+1

Not recruiting

Study on Elinzanetant for Treating Hot Flashes in Women with or at High Risk for Hormone-Receptor Positive Breast Cancer

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elinzanetant
  • Sponsor:Bayer AG

Gastric cancer

Not recruiting

Study of Bemarituzumab with Chemotherapy and Nivolumab in Untreated Advanced Gastric and Gastroesophageal Junction Cancer Patients with FGFR2b Overexpression

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Mannheim

What the registry says about research in the country

01 Neurodegenerative Disorders

Clinical investigations focusing on Alzheimer's Disease and ALS, including trials of new therapeutic compounds for early-stage dementia and innovative treatments for motor neuron disease.

  • Early-stage Alzheimer's diagnostic tools
  • Novel drug therapies for neurodegenerative conditions
  • Disease progression monitoring

Research aims to improve brain amyloid clearance and evaluate new treatment approaches for neurological disorders.

02 Oncology Research

Comprehensive studies in cancer treatment, including trials for gastric cancer, melanoma, and breast cancer, with a focus on targeted therapies and immunological approaches.

  • HER2-expressing cancers
  • Metastatic melanoma treatments
  • Lymphoma therapies

Advanced treatments combining immunotherapy with established protocols to improve patient outcomes.

03 Inflammatory Conditions

Studies addressing inflammatory disorders, particularly focusing on Crohn's Disease, ulcerative colitis, and uveitis, testing novel therapeutic combinations.

  • Gastrointestinal disorders
  • Autoimmune conditions
  • Combination therapy approaches

Innovative treatment strategies aimed at improving disease management and patient quality of life.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.